Biaryl Amides

1 . A method of treating an ocular hypertensive condition in a mammal or of providing neuroprotection to an eye of a mammal, comprising administering to a mammal in need thereof, a therapeutically effective amount of a compound of formula (1)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

X is OCH 2 , CH═CH or CH 2 ;

Y is —CO 2 or —C(O)NH;

Z is a straight or branched chain alkyl group of 1-6 carbon atoms, a cycloalkyl group of 1-6 carbon atoms, either of which may be optionally substituted with one or more groups selected from OH, CO 2 H, CONH 2 , OR 1 , CO 2 R 1 , CONHR 1 and OCO 2 R 1 ;

R 1 is a straight or branched chain alkyl group of 1-6 carbon atoms optionally substituted with one or more groups selected from OH, CO 2 H, CONH 2 , OR 2 , CO 2 R 2 and CONHR 2 ;

R 2 is selected from a straight or branched chain alkyl group of 1-6 carbon atoms optionally substituted with one or more groups independently selected from OH, CO 2 H, CONH 2 , OR 3 , CO 2 R 3 and CONHR 3 ; and

R 3 is a straight or branched chain alkyl group of 1-6 carbon atoms; or

YZ together form a group selected from

where Y and Z are as defined above.

2 . The method according to claim 1 , wherein X is OCH 2 .

3 . The method according to claim 1 , wherein YZ is CONH 2 .

4 . The method according to claim 1 , wherein Y is —CO 2 .

5 . The method according to claim 4 , wherein Z is a straight or branched chain alkyl group having 1, 2 or 3 carbon atoms.

6 . The method according to claim 4 , wherein Z is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl.

7 . The method according to claim 4 , wherein Z is substituted with 1 or 2 groups independently selected from the group consisting of OH and CO 2 H.

8 . The method according to claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

or a pharmaceutically acceptable salt or solvate thereof.

9 . The method according to claim 1 wherein the compound is:

or a pharmaceutically acceptable salt or solvate thereof.

10 . The method according to claim 1 wherein the compound is:

or a pharmaceutically acceptable solvate thereof.

11 . A compound of formula (1) as defined in claim 1 , or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compound does not have the structure:

12 . A compound of formula (2):

or a pharmaceutically acceptable salt or solvate wherein:

R 4 is independently selected from the group consisting of H, halogen, methyl, methoxy, hydroxy, trifluoromethyl and trifluoromethoxy;

R 5 is independently selected from the group consisting of H, halogen, methyl, methoxy, hydroxy, trifluoromethyl and trifluoromethoxy;

Q 2 is selected from a group consisting of CH, N and O;

each of Q 1 and Q 3 is independently a carbon or nitrogen atom;

each of W is independently selected from the group consisting of (CR) 0-1 , N, O and S where each R is independently selected from the group consisting of H, halogen, methyl, methoxy, hydroxy, trifluoromethyl and trifluoromethoxy;

n=1, 2 or 3; and

A=CH 2 , CH 2 CH 2 , CH═CH or OCH 2 .

13 . The compound according to claim 12 , wherein R 5 is H or F.

14 . The compound according to claim 12 , wherein A is OCH 2 .

15 . The compound according to claim 12 , wherein the compound is of formula (2a):

16 . The compound according to claim 12 , wherein the compound is of formula (2b):

17 . The compound according to claim 12 , wherein the group

has the structure:

18 . The compound according to claim 12 having the structure:

19 - 24 . (canceled)

25 . The method of claim 1 , wherein the method is a method of treating an ocular hypertensive condition.

26 . The method of claim 25 , wherein the condition is glaucoma.

27 . The method of claim 1 , wherein the method is a method of providing neuroprotection to an eye of a mammal.

28 . A pharmaceutical composition comprising a compound as defined in claim 1 , and a pharmaceutically acceptable carrier, diluent, preservative, buffer or antioxidant.

29 . A pharmaceutical composition comprising a compound according to claim 12 , and a pharmaceutically acceptable carrier, diluent, preservative, buffer or antioxidant.

30 . A contact lens or a contact lens solution comprising a compound as defined in claim 1 .

31 . A contact lens or a contact lens solution comprising a compound according to claim 12 .